Arcera Life Sciences releases inaugural Sustainability Report
The 2024 report outlines Arcera’s current ESG initiatives and long-term ambitions, including a firm commitment to achieving full carbon neutrality...
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer’s Disease
Seongnam-si, South Korea and Abu Dhabi, UAE – June 10, 2025 – AriBio Co., Ltd. (“AriBio”), a South Korean biopharmaceutical company...
Achieving Level 1 B-BBEE status in South Africa for the sixth year in a row
For the sixth consecutive year, Acino has achieved Level 1 Broad-Based Black Economic Empowerment (B-BBEE) contributor status in South Africa.
Leadership Announcements and New Arcera Structure
Arcera aims to become a global life sciences company, with the purpose of enabling longer and healthier lives while driving...
Acino signs an exclusive agreement with LG Chem for Novel Treatments for Type 2 Diabetes and Osteoarthritis in Latin America
Acino will market, commercialize, and distribute Hyruan One® in Brazil, and Zemiglo® and Zemimet® SR (Zemiduo® SR in Mexico) in...
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
ADQ launches holding company Arcera to build a global life sciences powerhouse anchored in Abu Dhabi
Abu Dhabi, UAE – 01/04/2024: ADQ, an Abu Dhabi-based investment and holding company, has announced the formation of Arcera, a...
Acquisition of M8 Pharmaceuticals and integration into Acino
With nearly 300 new employees on board, Acino will enhance its presence in Latin America and strengthen its business through...
ADQ to acquire leading Turkish pharmaceuticals company Birgi Mefar Group
ADQ to acquire leading Turkish Pharmaceutical Contract Development and Manufacturing Organization (CDMO) of sterile solutions and injectables.